Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Ultragenyx Pharmaceutical Inc RARE

Healthcare Biotechnology
Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company. The Company is focused on the identification, acquisition, development, and commercialization of novel products for the treatment of serious rare and ultrarare genetic diseases. Its therapies and clinical-stage pipeline consist of four product categories: biologics, small molecules, AAV gene therapy, and nucleic acid product... see more

Recent & Breaking News (NDAQ:RARE)

Ultragenyx to Host Conference Call for Second Quarter 2019 Financial Results and Corporate Update

GlobeNewswire July 23, 2019

Evolus Expands Board of Directors with Appointment of Independent Directors Peter Farrell, Ph.D. and Karah Parschauer, J.D.

GlobeNewswire July 15, 2019

Ultragenyx and Arcturus Therapeutics Expand Existing Research Collaboration and License Agreement to Develop Additional Nucleic Acid Therapies for Rare Diseases

GlobeNewswire June 19, 2019

Ultragenyx Expands Leadership Team and Promotes Erik Harris to Chief Commercial Officer

GlobeNewswire June 17, 2019

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire May 31, 2019

Ultragenyx Announces Emil D. Kakkis, M.D., Ph.D. as Recipient of BIO's 2019 Henri A. Termeer Biotechnology Visionary Award

GlobeNewswire May 29, 2019

Ultragenyx to Present at Bank of America Merrill Lynch Healthcare Conference

GlobeNewswire May 10, 2019

Ultragenyx Reports First Quarter 2019 Financial Results and Corporate Update

GlobeNewswire May 6, 2019

Ultragenyx to Host Conference Call for First Quarter 2019 Financial Results and Corporate Update

GlobeNewswire April 30, 2019

Ultragenyx to Present Corporate Update at Analyst and Investor Day on April 17 in New York

GlobeNewswire April 11, 2019

Ultragenyx Announces Approval of Crysvita® (burosumab) in Brazil for the Treatment of X-linked Hypophosphatemia (XLH) in Adults and Children

GlobeNewswire March 26, 2019

Ultragenyx to Present at Upcoming Investor Conferences

GlobeNewswire March 11, 2019

Ultragenyx Announces Pricing of Public Offering of Common Stock

GlobeNewswire February 26, 2019

Ultragenyx Announces Proposed Public Offering of Common Stock

GlobeNewswire February 25, 2019

Sell-Side Picks Top Gene Therapy Takeout Candidates Following Spark Therapeutics Deal

Benzinga.com  February 25, 2019

Ultragenyx Announces Positive 24-week Data from First Cohort of Phase 1/2 Study of DTX401 Gene Therapy in Glycogen Storage Disease Type Ia

GlobeNewswire February 21, 2019

Ultragenyx Reports Fourth Quarter and Full Year 2018 Financial Results and Corporate Update

GlobeNewswire February 19, 2019

Ultragenyx to Host Conference Call for Fourth Quarter and Full-Year 2018 Financial Results and Corporate Update

GlobeNewswire February 12, 2019

Ultragenyx Appoints Shehnaaz Suliman, M.D., to Board of Directors

GlobeNewswire February 4, 2019

Ultragenyx Announces Positive Topline Data from Ongoing Long-Term Extension Study of UX007 for the Treatment of Long-chain Fatty Acid Oxidation Disorders

GlobeNewswire January 22, 2019